Meeting
2021 ASCO Annual Meeting
Modeling the cost-effectiveness of adjuvant osimertinib in resected EGFR-mutant non-small cell lung cancer patients.
Authors
Christopher Lemmon
Cleveland Clinic, Cleveland, OH
Christopher Lemmon , Emily Craig Zabor , Nathan A. Pennell
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 8527)
DOI
10.1200/JCO.2021.39.15_suppl.8527
Abstract #
8527
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Quality Care Symposium
Comparative cost-effectiveness analysis of oral agents for advanced EGFR mutated and ALK-positive non-small cell lung cancer.
First Author: Dali Edwards
Poster
2023 ASCO Annual Meeting
Clinical and financial implications of ADUARA trial on a real-world population.
First Author: Bharathi Muthusamy
Poster
2023 ASCO Annual Meeting
Differential expression analysis of circRUNX1 in patients with early resected EGFR-mutant NSCLC.
First Author: Carlos Pedraz
Poster
2012 ASCO Annual Meeting
Vinorelbine plus cisplatin versus gefitinib in resected non-small cell lung cancer haboring activating EGFR mutation (WJOG6410L).
First Author: Hirohito Tada